Por favor, use este identificador para citar o enlazar este ítem: https://hdl.handle.net/10495/42301
Registro completo de metadatos
Campo DC Valor Lengua/Idioma
dc.contributor.authorBonilla Ramírez, Leonardo-
dc.contributor.authorGaliano, Silvia-
dc.contributor.authorQuiliano, Miguel-
dc.contributor.authorAldana, Ignacio-
dc.contributor.authorPabón Vidal, Adriana Lucía-
dc.date.accessioned2024-09-20T15:48:11Z-
dc.date.available2024-09-20T15:48:11Z-
dc.date.issued2019-
dc.identifier.citationBonilla-Ramírez L, Galiano S, Quiliano M, Aldana I, Pabón A. Primaquine-quinoxaline 1,4-di-N-oxide hybrids with action on the exo-erythrocytic forms of Plasmodium induce their effect by the production of reactive oxygen species. Malar J. 2019 Jun 19;18(1):201. doi: 10.1186/s12936-019-2825-8.spa
dc.identifier.urihttps://hdl.handle.net/10495/42301-
dc.description.abstractABSTRACT: Background: The challenge in anti-malarial chemotherapy is based on the emergence of resistance to drugs and the search for medicines against all stages of the life cycle of Plasmodium spp. as a therapeutic target. Nowadays, many molecules with anti-malarial activity are reported. However, few studies about the cellular and molecular mechanisms to understand their mode of action have been explored. Recently, new primaquine-based hybrids as new molecules with potential multi-acting anti-malarial activity were reported and two hybrids of primaquine linked to quinoxaline 1,4-di-N-oxide (PQ-QdNO) were identified as the most active against erythrocytic, exoerythrocytic and sporogonic stages. Methods: To further understand the anti-malarial mode of action (MA) of these hybrids, hepg2-CD81 were infected with Plasmodium yoelii 17XNL and treated with PQ-QdNO hybrids during 48 h. After were evaluated the production of ROS, the mitochondrial depolarization, the total glutathione content, the DNA damage and proteins related to oxidative stress and death cell. Results: In a preliminary analysis as tissue schizonticidals, these hybrids showed a mode of action dependent on peroxides production, but independent of the activation of transcription factor p53, mitochondrial depolarization and arrest cell cycle. Conclusions: Primaquine-quinoxaline 1,4-di-N-oxide hybrids exert their antiplasmodial activity in the exoerythrocytic phase by generating high levels of oxidative stress which promotes the increase of total glutathione levels, through oxidation stress sensor protein DJ-1. In addition, the role of HIF1a in the mode of action of quinoxaline 1,4-di-N-oxide is independent of biological activity. Keywords: 4-Di-N-oxide; Cell death; Exoerythrocytic stage; Malaria; Oxidative stress; Plasmodium; Quinoxaline 1.spa
dc.format.extent13 páginasspa
dc.format.mimetypeapplication/pdfspa
dc.language.isoengspa
dc.publisherBMC (BioMed Central)spa
dc.type.hasversioninfo:eu-repo/semantics/publishedVersionspa
dc.rightsinfo:eu-repo/semantics/openAccessspa
dc.rights.urihttp://creativecommons.org/licenses/by/2.5/co/*
dc.titlePrimaquine-quinoxaline 1,4-di-N-oxide hybrids with action on the exo-erythrocytic forms of Plasmodium induce their effect by the production of reactive oxygen speciesspa
dc.typeinfo:eu-repo/semantics/articlespa
dc.publisher.groupGrupo Malariaspa
dc.identifier.doi10.1186/s12936-019-2825-8.-
oaire.versionhttp://purl.org/coar/version/c_970fb48d4fbd8a85spa
dc.rights.accessrightshttp://purl.org/coar/access_right/c_abf2spa
dc.identifier.eissn1475-2875-
oaire.citationtitleMalaria Journalspa
oaire.citationstartpage1spa
oaire.citationendpage13spa
oaire.citationvolume18spa
oaire.citationissue1spa
dc.rights.creativecommonshttps://creativecommons.org/licenses/by/4.0/spa
oaire.fundernameColombia. Ministerio de Ciencia, Tecnología e Innovación - MinCienciasspa
oaire.fundernameUniversidad de Navarraspa
dc.publisher.placeLondres, Inglaterraspa
dc.type.coarhttp://purl.org/coar/resource_type/c_2df8fbb1spa
dc.type.redcolhttps://purl.org/redcol/resource_type/ARTspa
dc.type.localArtículo de investigaciónspa
dc.subject.decsAntimaláricos-
dc.subject.decsAntimalarials-
dc.subject.decsEritrocitos-
dc.subject.decsErythrocytes-
dc.subject.decsCélulas Hep G2-
dc.subject.decsHep G2 Cells-
dc.subject.decsPlasmodium yoelii-
dc.subject.decsPrimaquina-
dc.subject.decsPrimaquine-
dc.subject.decsQuinoxalinas-
dc.subject.decsQuinoxalines-
dc.subject.decsEsporozoítos-
dc.subject.decsSporozoites-
dc.description.researchgroupidCOL0024159spa
oaire.awardnumberMinCiencias 111571249992spa
oaire.awardnumberUNAV 70391spa
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D056945-
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D010600-
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D004912-
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D010967-
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D011319-
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D011810-
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D034101-
dc.relation.ispartofjournalabbrevMalar. J.spa
oaire.funderidentifier.rorRoR:03fd5ne08-
oaire.funderidentifier.rorRoR:02rxc7m23-
Aparece en las colecciones: Artículos de Revista en Ciencias Médicas

Ficheros en este ítem:
Fichero Descripción Tamaño Formato  
PabonAdriana_2019_Primiquine_Quinoxaline_Plasmodium.pdfArtículo de investigación2.3 MBAdobe PDFVisualizar/Abrir


Este ítem está sujeto a una licencia Creative Commons Licencia Creative Commons Creative Commons